WuXi XDC Cayman, Inc. stock analysis
Want to see HK:2268 full AI Analyst Report?
WuXi XDC Cayman, Inc. (2268) Stock Price & Analysis
2268 Stock Chart & Stats
- Day’s Range
- HKD 69.20 - HKD 73.20
- 52-Week Range
- HKD 43.50 - HKD 85.60
- Previous Close
- HKD 73.15
- Volume
- N/A
- Average Volume (3M)
- 5.03M
- Market Cap
- HKD 92.97B
- Enterprise Value
- HKD 72.45B
- Total Cash (Recent Filing)
- HKD 5.73B
- Total Debt (Recent Filing)
- HKD 531.43M
- Price to Earnings (P/E)
- 50.2
- Beta
- 0.80
- Next Earnings
- Mar 29, 2027 (Est.)
- EPS Estimate
- 0.93
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Profitability
Strong revenue growth combined with high net and operating margins indicates meaningful demand and profitable execution. If these economics persist, the company can fund development, absorb competitive pressure, and build earnings power over the next several quarters.
Conservative Balance Sheet
Very low leverage and substantial equity provide financial resilience and preserve flexibility for investment in capabilities, capacity, or customer programs. The modest debt burden also reduces interest-related pressure and improves the company’s ability to withstand operating volatility.
Integrated Complex-Therapeutics Services
Serving multiple stages of the drug lifecycle gives the company a broader role in customers’ development programs than a single-service provider. Its focus on complex therapeutics can support recurring project opportunities as customers advance programs from research toward manufacturing.
Bears Say
Volatile Free Cash Flow
Uneven free cash flow indicates that accounting profitability has not consistently translated into discretionary cash generation. Volatility can constrain internally funded expansion and make capital allocation less predictable, particularly when reinvestment or capital spending needs rise.
Margin Compression
Lower margins while the business scales suggest cost intensity is increasing and that growth is not fully converting into incremental profitability. Sustained compression would reduce operating leverage, weaken earnings resilience, and limit the benefit of future revenue expansion.
Lower Return On Equity
The decline in return on equity indicates that the company generated less profit per unit of shareholder capital than in the prior year. If the trend continues, it could signal weaker capital efficiency and reduce the long-term attractiveness of reinvesting retained earnings.
WuXi XDC Cayman, Inc. News
WuXi XDC Unit BioDlink Signs RMB19 Million Monoclonal Antibody Manufacturing Deal With WuXi Biologics
WuXi XDC Cayman, Inc. ( ($HK:2268) ) has issued an update. WuXi XDC’s subsidiary BioDlink International has signed a process development and manufacturing services agreement with WuXi Biologics, under which
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
What is WuXi XDC Cayman, Inc.’s market cap?
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
Is WuXi XDC Cayman, Inc. overvalued?
Does WuXi XDC Cayman, Inc. pay dividends?
What is WuXi XDC Cayman, Inc.’s EPS estimate?
How many shares outstanding does WuXi XDC Cayman, Inc. have?
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
What is the TipRanks Smart Score and how is it calculated?
WuXi XDC Cayman, Inc. Stock Smart Score
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jincai Li
- Employees
- 2,662
- Website
- wuxixdc.com
- Address
- CN
WuXi XDC Cayman, Inc. (2268) Earnings & Revenues
2268 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 10 | 0 | 2 |









